Ototoxicity in children treated for osteosarcoma

Matthew J. Lewis, Steven G. Dubois, Brian Fligor, Xiaochun Li, Allen Goorin, Holcombe E. Grier

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background. Cisplatin is an effective agent against osteosarcoma. Ototoxicity from osteosarcoma treatment protocols has not been well defined. The aim of this study was to determine the incidence and risk factors for hearing loss in children treated for osteosarcoma. Procedure. Eligible patients had osteosarcoma diagnosed and treated atthe Dana-Farber Cancer Institute/Children's Hospital Boston from January 1, 1995 to December 12, 2004, were 3-18 years of age at diagnosis, and had a normal audiogram prior to the start of chemotherapy. Patients received cisplatin according to the standard practice or current open protocol. Patients who developed hearing loss during treatment had cisplatin held on an individualized basis. Hearing function was evaluated prior to the startof therapy, before each cycle, and off-therapy. Fisher's exacttest and logistic regression models were used to identify univariate and independent predictors of hearing loss, respectively. Results. Seven out of nine patients(78%) who received cisplatin l2o mg/m 2/day on 1 day developed hearing loss compared to 8/27(30%) who received 60 mg/m2/day for 2 days(P = 0.019). Logistic regression showed that age, cumulative cisplatin dose, and administration of cisplatin 120 mg/m2/day were independent predictors of hearing loss. Cisplatin administered as 60 mg/m 2/day for 2 days resulted in a low incidence(30%) of any hearing loss and a very low incidence(4%) of educationally significant hearing loss. Conclusions. Cisplatin administered as 60 mg/m2/day for 2 days resulted in a low incidence of significant hearing loss. These results suggest that cisplatin as 120 mg/m 2/day be avoided due to an unacceptable incidence of hearing loss.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
JournalPediatric Blood and Cancer
Volume52
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Osteosarcoma
Hearing Loss
Cisplatin
Incidence
Logistic Models
Clinical Protocols
Hearing
Therapeutics
Drug Therapy

Keywords

  • Cisplatin
  • Hearing loss
  • Osteosarcoma
  • Ototoxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Lewis, M. J., Dubois, S. G., Fligor, B., Li, X., Goorin, A., & Grier, H. E. (2009). Ototoxicity in children treated for osteosarcoma. Pediatric Blood and Cancer, 52(3), 387-391. https://doi.org/10.1002/pbc.21875

Ototoxicity in children treated for osteosarcoma. / Lewis, Matthew J.; Dubois, Steven G.; Fligor, Brian; Li, Xiaochun; Goorin, Allen; Grier, Holcombe E.

In: Pediatric Blood and Cancer, Vol. 52, No. 3, 01.03.2009, p. 387-391.

Research output: Contribution to journalArticle

Lewis, MJ, Dubois, SG, Fligor, B, Li, X, Goorin, A & Grier, HE 2009, 'Ototoxicity in children treated for osteosarcoma', Pediatric Blood and Cancer, vol. 52, no. 3, pp. 387-391. https://doi.org/10.1002/pbc.21875
Lewis MJ, Dubois SG, Fligor B, Li X, Goorin A, Grier HE. Ototoxicity in children treated for osteosarcoma. Pediatric Blood and Cancer. 2009 Mar 1;52(3):387-391. https://doi.org/10.1002/pbc.21875
Lewis, Matthew J. ; Dubois, Steven G. ; Fligor, Brian ; Li, Xiaochun ; Goorin, Allen ; Grier, Holcombe E. / Ototoxicity in children treated for osteosarcoma. In: Pediatric Blood and Cancer. 2009 ; Vol. 52, No. 3. pp. 387-391.
@article{041a6c0b4a074e15b5a2290d0c3e1d36,
title = "Ototoxicity in children treated for osteosarcoma",
abstract = "Background. Cisplatin is an effective agent against osteosarcoma. Ototoxicity from osteosarcoma treatment protocols has not been well defined. The aim of this study was to determine the incidence and risk factors for hearing loss in children treated for osteosarcoma. Procedure. Eligible patients had osteosarcoma diagnosed and treated atthe Dana-Farber Cancer Institute/Children's Hospital Boston from January 1, 1995 to December 12, 2004, were 3-18 years of age at diagnosis, and had a normal audiogram prior to the start of chemotherapy. Patients received cisplatin according to the standard practice or current open protocol. Patients who developed hearing loss during treatment had cisplatin held on an individualized basis. Hearing function was evaluated prior to the startof therapy, before each cycle, and off-therapy. Fisher's exacttest and logistic regression models were used to identify univariate and independent predictors of hearing loss, respectively. Results. Seven out of nine patients(78{\%}) who received cisplatin l2o mg/m 2/day on 1 day developed hearing loss compared to 8/27(30{\%}) who received 60 mg/m2/day for 2 days(P = 0.019). Logistic regression showed that age, cumulative cisplatin dose, and administration of cisplatin 120 mg/m2/day were independent predictors of hearing loss. Cisplatin administered as 60 mg/m 2/day for 2 days resulted in a low incidence(30{\%}) of any hearing loss and a very low incidence(4{\%}) of educationally significant hearing loss. Conclusions. Cisplatin administered as 60 mg/m2/day for 2 days resulted in a low incidence of significant hearing loss. These results suggest that cisplatin as 120 mg/m 2/day be avoided due to an unacceptable incidence of hearing loss.",
keywords = "Cisplatin, Hearing loss, Osteosarcoma, Ototoxicity",
author = "Lewis, {Matthew J.} and Dubois, {Steven G.} and Brian Fligor and Xiaochun Li and Allen Goorin and Grier, {Holcombe E.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1002/pbc.21875",
language = "English (US)",
volume = "52",
pages = "387--391",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Ototoxicity in children treated for osteosarcoma

AU - Lewis, Matthew J.

AU - Dubois, Steven G.

AU - Fligor, Brian

AU - Li, Xiaochun

AU - Goorin, Allen

AU - Grier, Holcombe E.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background. Cisplatin is an effective agent against osteosarcoma. Ototoxicity from osteosarcoma treatment protocols has not been well defined. The aim of this study was to determine the incidence and risk factors for hearing loss in children treated for osteosarcoma. Procedure. Eligible patients had osteosarcoma diagnosed and treated atthe Dana-Farber Cancer Institute/Children's Hospital Boston from January 1, 1995 to December 12, 2004, were 3-18 years of age at diagnosis, and had a normal audiogram prior to the start of chemotherapy. Patients received cisplatin according to the standard practice or current open protocol. Patients who developed hearing loss during treatment had cisplatin held on an individualized basis. Hearing function was evaluated prior to the startof therapy, before each cycle, and off-therapy. Fisher's exacttest and logistic regression models were used to identify univariate and independent predictors of hearing loss, respectively. Results. Seven out of nine patients(78%) who received cisplatin l2o mg/m 2/day on 1 day developed hearing loss compared to 8/27(30%) who received 60 mg/m2/day for 2 days(P = 0.019). Logistic regression showed that age, cumulative cisplatin dose, and administration of cisplatin 120 mg/m2/day were independent predictors of hearing loss. Cisplatin administered as 60 mg/m 2/day for 2 days resulted in a low incidence(30%) of any hearing loss and a very low incidence(4%) of educationally significant hearing loss. Conclusions. Cisplatin administered as 60 mg/m2/day for 2 days resulted in a low incidence of significant hearing loss. These results suggest that cisplatin as 120 mg/m 2/day be avoided due to an unacceptable incidence of hearing loss.

AB - Background. Cisplatin is an effective agent against osteosarcoma. Ototoxicity from osteosarcoma treatment protocols has not been well defined. The aim of this study was to determine the incidence and risk factors for hearing loss in children treated for osteosarcoma. Procedure. Eligible patients had osteosarcoma diagnosed and treated atthe Dana-Farber Cancer Institute/Children's Hospital Boston from January 1, 1995 to December 12, 2004, were 3-18 years of age at diagnosis, and had a normal audiogram prior to the start of chemotherapy. Patients received cisplatin according to the standard practice or current open protocol. Patients who developed hearing loss during treatment had cisplatin held on an individualized basis. Hearing function was evaluated prior to the startof therapy, before each cycle, and off-therapy. Fisher's exacttest and logistic regression models were used to identify univariate and independent predictors of hearing loss, respectively. Results. Seven out of nine patients(78%) who received cisplatin l2o mg/m 2/day on 1 day developed hearing loss compared to 8/27(30%) who received 60 mg/m2/day for 2 days(P = 0.019). Logistic regression showed that age, cumulative cisplatin dose, and administration of cisplatin 120 mg/m2/day were independent predictors of hearing loss. Cisplatin administered as 60 mg/m 2/day for 2 days resulted in a low incidence(30%) of any hearing loss and a very low incidence(4%) of educationally significant hearing loss. Conclusions. Cisplatin administered as 60 mg/m2/day for 2 days resulted in a low incidence of significant hearing loss. These results suggest that cisplatin as 120 mg/m 2/day be avoided due to an unacceptable incidence of hearing loss.

KW - Cisplatin

KW - Hearing loss

KW - Osteosarcoma

KW - Ototoxicity

UR - http://www.scopus.com/inward/record.url?scp=58949096530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949096530&partnerID=8YFLogxK

U2 - 10.1002/pbc.21875

DO - 10.1002/pbc.21875

M3 - Article

C2 - 19061216

AN - SCOPUS:58949096530

VL - 52

SP - 387

EP - 391

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -